Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents. However, COX-2 inhibitors decrease prostacyclin production and may disrupt the normal homeostatic balance, leading to a prothrombotic state and...
Sábháilte in:
| Foilsithe in: | Arthritis Res Ther |
|---|---|
| Príomhchruthaitheoirí: | , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
BMC
2002
|
| Ábhair: | |
| Rochtain ar líne: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC154429/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12716442/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/ar609 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|